← Leaderboards
Zhi-Ping Liu
Ut Southwestern Medical Center
$6,770,219
Attributed
$8,014,041
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,014,041 · 5
By mechanism
R01$7,559,041 · 4
R41$455,000 · 1
Top collaborators
- Jer-Tsong Hsieh7 shared
- Jung-Mo Ahn2 shared
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Xuewu Zhang$8,675,924
- Kathia E. Rodarte$106,342
- Mark Borromeo$86,529
- Joseph A. Hill$28,732,318
- Xiankai Sun$2,349,984
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignMolecularPharmaceutical PreparationsGene ExpressionSuccessGenesPlayTransgenic MicePhysiologicalIn VivoLeadEffective TherapyGenetic TranscriptionBaseSignal PathwayMalignant NeoplasmsKnockout MiceEpigenetic ProcessFutureInflammationProductionMyocardial InfarctionCytokineInflammatory
Grant awards (21)
Role of Cilp1 in Post-Natal Heart Response to Injury$544,734
R01 · FY2025 · HL · contact PI
Role of Cilp1 in Post-Natal Heart Response to Injury$533,839
R01 · FY2024 · HL · contact PI
Role of Cilp1 in Post-Natal Heart Response to Injury$544,734
R01 · FY2023 · HL · contact PI
Role of Cilp1 in Post-Natal Heart Response to Injury$560,734
R01 · FY2022 · HL · contact PI
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)$405,500
R01 · FY2022 · CA · contact PI
Development of small molecule epigenetic therapeutics for prostate cancer$55,000
R41 · FY2022 · CA · contact PI
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)$413,776
R01 · FY2021 · CA · contact PI
Development of small molecule epigenetic therapeutics for prostate cancer$400,000
R41 · FY2021 · CA · contact PI
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)$231,063
R01 · FY2020 · CA · contact PI
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)$401,363
R01 · FY2019 · CA · contact PI
Targeting KDM4B, a novel alternative splicing regulator, in castration-resistant prostate cancer (CRPC)$429,276
R01 · FY2018 · CA · contact PI
Epigenetic Regulation of Cardiac Hypertrophy and Heart Failure$391,537
R01 · FY2015 · HL · contact PI
Epigenetic Regulation of Cardiac Hypertrophy and Heart Failure$389,550
R01 · FY2014 · HL · contact PI
Epigenetic Regulation of Cardiac Hypertrophy and Heart Failure$378,420
R01 · FY2013 · HL · contact PI
Epigenetic Regulation of Cardiac Hypertrophy and Heart Failure$397,291
R01 · FY2012 · HL · contact PI
Role of FOXO4 in atherosclerosis$343,006
R01 · FY2010 · HL · contact PI
Role of FOXO4 in atherosclerosis$343,006
R01 · FY2009 · HL · contact PI
Role of FOXO4 in atherosclerosis$211,950
R01 · FY2009 · HL · contact PI
Role of FOXO4 in atherosclerosis$343,006
R01 · FY2008 · HL · contact PI
Role of FOXO4 in atherosclerosis$343,006
R01 · FY2007 · HL · contact PI
Role of FOXO4 in atherosclerosis$353,250
R01 · FY2006 · HL · contact PI